MedPath

Analysis of Various Treatment Methods of Granulomatous Lobular Mastitis

Recruiting
Conditions
Granulomatous Mastitis
Interventions
Procedure: Surgery
Drug: triple anti-tuberculosis drug
Registration Number
NCT06565845
Lead Sponsor
First Affiliated Hospital of Harbin Medical University
Brief Summary

Granulomatous lobular mastitis (GLM) is a rare benign breast disease that is difficult to distinguish from breast cancer based on clinical and imaging findings, and there is currently no standard treatment. This study aims to analyze the clinical characteristics and demographic data of GLM patients and to compare the overall effectiveness of three treatment methods: surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy, with the goal of providing new insights for clinical treatment.

Detailed Description

In recent years, the incidence of this disease has been increasing annually. The incidence of GLM is region-specific, being higher in Mediterranean regions and Asian countries. The etiology is currently unclear, but many studies suggest that GLM is associated with autoimmune disorders, hormonal imbalances, and microbial infections . GLM has a long course, is difficult to treat, and prone to recurrence, causing significant trauma to the patient's breast appearance and overall well-being. Currently, the main treatment methods for GLM include surgical treatment, drug therapy, combined surgery with drug therapy, and close observation. Surgical treatment options mainly include abscess incision and drainage, segmental resection, subcutaneous mastectomy, mastectomy, and breast reconstruction. Although surgical treatment can rapidly improve the condition, the recurrence rate reported in the literature ranges from 5% to 50% . Although GLM is a benign disease, it can severely impact the patient's normal life, causing physical and psychological trauma. However, few studies have included patients' subjective treatment experiences in the evaluation of treatment outcomes.

To date, there have been no studies comparing the efficacy of three treatment methods (surgery alone, triple anti-tuberculosis drug therapy alone, and combined surgery with triple anti-tuberculosis drug therapy) in the same population of GLM patients. This study aims to compare the efficacy and patient satisfaction of these three treatment methods, with the hope of providing new insights for clinical treatment options.

Recruitment & Eligibility

Status
RECRUITING
Sex
Female
Target Recruitment
350
Inclusion Criteria
  • non-lactating and aged 15-65 years
  • histopathological confirmation of GLM
  • normal liver and kidney function
Exclusion Criteria
  • lactating and pregnant women
  • allergies to rifampin, isoniazid, or ethambutol
  • concurrent malignant breast tumors
  • severe underlying diseases
  • other conditions deemed unsuitable by the investigator and
  • refusal to participate in the study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
surgery groupSurgeryThe patients underwent surgery
triple anti-tuberculosis drug therapy grouptriple anti-tuberculosis drugThe patients were treated with triple anti-tuberculosis drugs
combination therapy groupSurgeryThe patients were treated with surgery first, and then took triple anti-tuberculosis drugs after surgery
combination therapy grouptriple anti-tuberculosis drugThe patients were treated with surgery first, and then took triple anti-tuberculosis drugs after surgery
Primary Outcome Measures
NameTimeMethod
Differences in the cure rate of the three treatment modalitiesBaseline

According to the treatment method, the patients were divided into three groups: surgery group, triple anti-TB drug treatment group, and combination treatment group. IBM SPSS 27.0 software was used for statistical analysis. The cure rate was compared among the three groups.

Differences in the recurrence rate of the three treatment modalitiesBaseline

According to the treatment method, the patients were divided into three groups: surgery group, triple anti-TB drug treatment group, and combination treatment group. IBM SPSS 27.0 software was used for statistical analysis. The recurrence rate was compared among the three groups.

Differences in the incidence of adverse reactions of the three treatment modalitiesBaseline

According to the treatment method, the patients were divided into three groups: surgery group, triple anti-TB drug treatment group, and combination treatment group. IBM SPSS 27.0 software was used for statistical analysis. The incidence of adverse reactions was compared among the three groups.

Secondary Outcome Measures
NameTimeMethod
Differences in the treatment duration (months) of the three treatment modalitiesBaseline

According to the treatment method, the patients were divided into three groups: surgery group, triple anti-TB drug treatment group, and combination treatment group. IBM SPSS 27.0 software was used for statistical analysis. The treatment duration (months) was compared among the three groups.

Differences in the patient satisfaction score (points) of the three treatment modalitiesBaseline

According to the treatment method, the patients were divided into three groups: surgery group, triple anti-TB drug treatment group, and combination treatment group. IBM SPSS 27.0 software was used for statistical analysis. The patient satisfaction score (points) was compared among the three groups.

Trial Locations

Locations (1)

First affiliated hospital of Harbin medical university

🇨🇳

Harbin, Heilongjiang, China

© Copyright 2025. All Rights Reserved by MedPath